Download Free Sample Report

Global Cholesterol-Lowering Drugs Market Research Report 2023

Global Cholesterol-Lowering Drugs Market Research Report 2023

  • Published on : 17 December 2022
  • Pages :92
  • Report Code:SMR-7513285

Download Report PDF Instantly

Leave This Empty:

Secure

Report overview

Due to the COVID-19 pandemic, the global Cholesterol-Lowering Drugs market size is estimated to be worth US$ 17440 million in 2022 and is forecast to a readjusted size of US$ 21170 million by 2030 with a CAGR of 2.8% during the forecast period 2023-2030.

Fully considering the economic change by this health crisis, the Europe Cholesterol-Lowering Drugs market is estimated at US$ million in 2023, while the United States and China are forecast to reach US$ million and US$ million by 2030, respectively. The proportion of the United States is % in 2023, while Chinese percentage is %, and it is predicted that China market share will reach % in 2030, trailing a CAGR of % through the analysis period. As for the Europe Cholesterol-Lowering Drugs landscape, Germany is projected to reach US$ million by 2030. and in Asia, the notable markets are Japan and South Korea, CAGR is % and % respectively for the next 6-year period.
Statins accounting for % of the Cholesterol-Lowering Drugs global market in 2022, is projected to value US$ million by 2030, growing at a revised % CAGR from 2023 to 2030. While Hospital segment is altered to an % CAGR throughout this forecast period and will hold a share about % in 2030.
The global major manufacturers of Cholesterol-Lowering Drugs include AstraZeneca, Merck, Pfizer, Kowa, Daiichi Sankyo, AbbVie, Novartis, Sanofi and Amgen and etc. In terms of revenue, the global 3 largest players have a % market share of Cholesterol-Lowering Drugs in 2022.
This report focuses on Cholesterol-Lowering Drugs volume and value at the global level, regional level, and company level. From a global perspective, this report represents overall Cholesterol-Lowering Drugs market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan, etc.


Global Cholesterol-Lowering Drugs Market: Segment Analysis

The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2018 to 2030. Understanding the segments helps in identifying the importance of different factors that aid the market growth.

Segment by Type

  • Statins
  • Cholesterol Absorption Inhibitors
  • Fibrates
  • PCSK9 Inhibitors

Segment by Application

  • Hospital
  • Household
  • Other

By Region

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • France
  • U.K.
  • Italy
  • Russia
  • Asia-Pacific
  • China
  • Japan
  • South Korea
  • India
  • Australia
  • Taiwan
  • Indonesia
  • Thailand
  • Malaysia
  • Philippines
  • Vietnam
  • Latin America
  • Mexico
  • Brazil
  • Argentina
  • Middle East & Africa
  • Turkey
  • Saudi Arabia
  • UAE

By Company

  • AstraZeneca
  • Merck
  • Pfizer
  • Kowa
  • Daiichi Sankyo
  • AbbVie
  • Novartis
  • Sanofi
  • Amgen
  • Bristol-Myers Squibb